Skip to content
Back to search results

Skindex-29 (Skin Disease Quality of Life Instrument)

Introduced by
Chren MM, Lasek RJ
Year
1997
Type
Self-report
Family
quality-of-life
Font size

What does it do?

Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning.

Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes.

The intuition behind the method

Skin diseases cause suffering that extends beyond the lesions themselves: social embarrassment, emotional distress, and functional limitation (work, recreation, intimacy). A clinician-assessed severity score like PASI or EASI may show improvement while patients still struggle with pruritus, sleep disruption, or self-consciousness. Skindex-29 captures these dimensions explicitly by asking patients about specific symptoms (itching, pain, burning), emotional responses (embarrassment, frustration), and functional impacts (work, social activities, sleep). This makes it essential for understanding true treatment benefit.

History

Skindex-29 was developed and published in 1997 by Chren and colleagues at the University of California, San Francisco, who conducted extensive qualitative and quantitative research on the quality-of-life burden of skin diseases. They identified three core domains (symptoms, emotions, functioning) through patient interviews and generated items reflecting these domains. The tool was validated in multiple dermatological conditions and populations. A shorter version, Skindex-16, was subsequently developed for brevity. Skindex-29 has been translated into numerous languages and used in trials of diverse therapies (topical, phototherapy, systemic, biologic). It is endorsed by major dermatological societies and increasingly required by regulatory agencies (FDA, EMA) in trials of dermatological drugs to demonstrate not only clinical benefit but quality-of-life improvement.

When to use it

Skindex-29 is appropriate for any patient with a skin disease, regardless of severity or clinical type. It is particularly valuable in trials of conditions with high quality-of-life burden (acne, atopic dermatitis, psoriasis, alopecia, vitiligo, ichthyosis) to ensure treatment efficacy encompasses not only clinical improvement but emotional and functional benefit. Skindex-29 is also used in observational studies to quantify disease burden in specific populations and to identify patients at high risk of depression or social isolation. In clinical practice, periodic Skindex-29 assessment (baseline, 8–12 weeks, 6 months) helps identify patients whose quality of life is not improving despite objective clinical progress and may indicate need for psychological support or therapy adjustment.

Limitations and considerations

  • Subjective recall; patients' memory of QoL impact over the past month may vary with current mood or recent events.
  • No clinician-rated version; cannot be completed by proxy (unlike DLQI variants for young children).
  • Ceiling effects possible in very mild disease; patients with minimal QoL impact may score near zero across all items.
  • Does not capture objective disease severity; a patient with severe psoriasis but high coping may score lower than a patient with mild disease and high distress.
  • Symptom items focus on subjective perception (itching, burning) rather than objective clinical signs; does not replace clinical assessment.
  • Recall period of 'past month' is fixed; adaptation for different assessment intervals is not formally validated.

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Patient-centered; directly captures impact on emotions, functioning, and daily symptoms rather than clinical signs.
  • Multidimensional; three subscales enable nuanced understanding of which QoL domains are most affected.
  • Broadly applicable; validated across all major skin diseases (eczema, psoriasis, acne, alopecia, vitiligo) and diverse populations.
  • Responsive to treatment; sensitive to clinically meaningful change with both topical and systemic therapies.
  • Practical; brief (29 items, 5–10 minutes) self-administered format suitable for routine clinical use and trials.
  • Validated translations available in 15+ languages.
  • Strong psychometric properties: internal consistency, test-retest reliability, construct validity.
  • Emotional subscale particularly sensitive in conditions with psychological burden (acne, alopecia).

Applications

  • Clinical trial endpoint: Co-primary or secondary patient-reported outcome measure in randomized trials of dermatological therapies, particularly for conditions with high emotional burden (acne, alopecia, vitiligo, psoriasis).
  • Observational burden-of-disease studies: Quantifying quality-of-life impact across skin disease subtypes and populations to inform public health priorities and healthcare resource allocation.
  • Clinical practice monitoring: Periodic assessment (baseline, 8–12 weeks, 6 months) to identify patients whose quality of life is not improving despite clinical improvement, triggering psychological referral or therapy adjustment.
  • Health-related quality-of-life research: Comparative effectiveness studies evaluating not only clinical efficacy but patient-centered outcomes across competing treatments.

How it works

How it works

1

The patient completes a 29-item self-administered questionnaire, typically in a clinic, at home, or online. Each item asks 'How much has your skin condition bothered you during the past month?' with response options on a Likert scale (0=not bothered/not at all to 4 or 5=extremely bothered/all the time). Items are organized into three domains: Symptoms (7 items, e.g., itching, pain, burning), Emotions (10 items, e.g., embarrassment, frustration, anxiety), and Functioning (12 items, e.g., impact on work, social activities, clothing choices, sleep). Completion takes 5–10 minutes.

Formula
Patient completes 29-item self-administered questionnaire. Each item asks about impact of skin disease over the past month on specific domains: symptoms, emotions, or functioning. Response scale is 0–4 Likert or 0–5 frequency scale (never, rarely, sometimes, often, all the time).
2

Skindex-29 yields three subscale scores and an overall score. Each subscale is calculated as the mean of its items converted to a 0–100 scale: Symptoms subscale (7 items × 0–100), Emotions subscale (10 items × 0–100), Functioning subscale (12 items × 0–100). The Overall Skindex-29 is the mean of all three subscale scores (0–100). Higher scores indicate greater negative impact and QoL burden.

Formula
Three subscales: Symptoms (7 items, 0–28), Emotions (10 items, 0–40), Functioning (12 items, 0–48). Total Skindex-29 = mean of three subscales, each converted to 0–100 scale. Overall Skindex-29 = mean of all 29 item scores × 100.
3

Subscale and overall scores range from 0–100. Scores of 0–25 indicate minimal impact; 25–50 indicate mild-to-moderate impact; 50–75 indicate moderate-to-substantial impact; >75 indicate severe impact on quality of life. A change of ≥8 points on any subscale represents meaningful clinical improvement (MCID). The Emotions subscale is often the most sensitive to treatment benefit in psychologically burdening conditions (acne, vitiligo, alopecia).

Formula
Each subscale scored 0–100. Higher score = greater negative impact (more impairment). Scores of 0–50 indicate low-to-moderate impact; >50 indicate substantial QoL burden. Change of ≥8 points per subscale indicates meaningful improvement.

Common pitfalls

  • Interpreting high Skindex-29 scores as indication that clinical treatment has failed; high QoL burden may reflect long-standing disease, poor adjustment, or comorbid mental health conditions. Psychological support or referral to psychiatry may be appropriate in addition to dermatological treatment.
  • Using only Skindex-29 without objective severity measures (PASI, EASI, SCORAD); regulatory agencies require both clinical efficacy and QoL outcomes, so always use together.
  • Assuming all three subscales are equally important for all conditions; in acne, the Emotions subscale is typically most affected; in psoriasis, Functioning may dominate. Report all three and highlight the most impacted domain.
  • Failing to administer Skindex-29 at multiple timepoints; a single timepoint does not establish treatment responsiveness. Measure at baseline, 8–12 weeks, and final visit minimum.
  • Misinterpreting scale direction; remember that HIGHER Skindex-29 scores = WORSE QoL (not better). Do not confuse with other scales where higher = improvement.

Frequently asked questions

Should Skindex-29 be used alongside PASI, EASI, or SCORAD in trials?

Yes. Objective clinical measures (PASI, EASI, SCORAD) and quality-of-life measures (Skindex-29, DLQI) are complementary. Many modern trials use both as co-primary or primary + secondary endpoints. This ensures treatments are evaluated not only for clinical efficacy but for meaningful improvement in patients' daily lives and emotional well-being.

What is the MCID for Skindex-29?

A change of ≥8 points on any Skindex-29 subscale (out of 100) is considered clinically meaningful improvement. For the overall Skindex-29 score, an 8-point reduction (out of 100) indicates improvement. Always report baseline and endpoint scores, as well as percentage change, to contextualize meaningfulness.

How does Skindex-29 compare to DLQI (Dermatology Life Quality Index)?

Both measure QoL impact in dermatological disease. DLQI has 10 items and focuses on functioning and social impact. Skindex-29 has 29 items and provides more granular assessment of symptoms, emotions, and functioning separately. For clinical trials, DLQI is often preferred for brevity; for detailed QoL assessment, Skindex-29 is superior. Choose based on study goals and respondent burden tolerance.

Can Skindex-29 be completed by parents for children?

The original Skindex-29 is not validated for proxy completion. However, for children aged 8+, direct self-administration is typically feasible. For younger children, the Skindex-Child variant (if available) is preferred. Always verify language level and reading comprehension; simplified versions may be needed for children under age 10.

How should high Skindex-29 scores be interpreted clinically?

High scores (>50) indicate substantial QoL burden and warrant psychological assessment and possible referral for mental health support in addition to dermatological treatment. Do not assume clinical treatment escalation alone will resolve QoL impact; assess for depression, anxiety, and social isolation.

Related methods

Sources

  1. Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713.

    Open DOI reference
    Copied.
  2. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433-1440.

    Open DOI reference
    Copied.